Literature DB >> 22698856

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.

Yousif Ahmad, Gregory Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22698856     DOI： 10.1136/heartjnl-2012-302101

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  10 in total

Review 1.  Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  The new oral anticoagulants: new uncertainties for endoscopists.

Authors:  Andrew Veitch
Journal:  Frontline Gastroenterol       Date:  2013-05-30

Review 3.  Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.

Authors:  Savino Sciascia; Massimo Radin; Karen Schreiber; Roberta Fenoglio; Simone Baldovino; Dario Roccatello
Journal:  Intern Emerg Med       Date:  2017-09-19       Impact factor: 3.397

Review 4.  Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants.

Authors:  Charalampos Kasmeridis; Stavros Apostolakis; Lars Ehlers; Lars H Rasmussen; Giuseppe Boriani; Gregory Y H Lip
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

Review 5.  Use of new oral anticoagulants in antiphospholipid syndrome.

Authors:  Deepa Jayakody Arachchillage; Hannah Cohen
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

6.  Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study.

Authors:  Peter K Maccallum; Rohini Mathur; Sally A Hull; Khalid Saja; Laura Green; Joan K Morris; Neil Ashman
Journal:  BMJ Open       Date:  2013-09-27       Impact factor: 2.692

Review 7.  The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.

Authors:  Raza Alikhan; Rachel Rayment; David Keeling; Trevor Baglin; Gary Benson; Laura Green; Scott Marshall; Raj Patel; Sue Pavord; Peter Rose; Campbell Tait
Journal:  Emerg Med J       Date:  2013-02-22       Impact factor: 2.740

Review 8.  Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.

Authors:  Brian Godman; Rickard E Malmström; Eduardo Diogene; Sisira Jayathissa; Stuart McTaggart; Thomas Cars; Samantha Alvarez-Madrazo; Christoph Baumgärtel; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Irene Eriksson; Alexander Finlayson; Jurij Fürst; Kristina Garuoliene; Iñaki Gutiérrez-Ibarluzea; Krystyna Hviding; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Kamila Malinowska; Hanne B Pedersen; Vanda Markovic-Pekovic; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Susan Spillane; Dominik Tomek; Luka Vončina; Vera Vlahović-Palčevski; Janet Wale; Magdalena Wladysiuk; Menno van Woerkom; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-10       Impact factor: 5.810

9.  Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis.

Authors:  Ehsan Rezaei-Darzi; Parinaz Mehdipour; Mariachiara Di Cesare; Farshad Farzadfar; Shadi Rahimzadeh; Lisa Nissen; Alireza Ahmadvand
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

10.  [Author's reply].

Authors:  José M Lobos Bejarano; José Polo García; Diego Vargas Ortega
Journal:  Aten Primaria       Date:  2014-07-06       Impact factor: 1.137
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.